businesspress24.com - Microbix Announces Annual Meeting Voting Results
 

Microbix Announces Annual Meeting Voting Results

ID: 1495737

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 03/30/17 -- Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, announces the results of the Annual Meeting of Shareholders which was held on March 29, 2017, at which 37.07% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the meeting. A detailed description of all resolutions that were voted on can be reviewed in the Company''s Information Circular which was filed on SEDAR on February 22, 2017. All of the director nominees listed in the Information Circular were re-elected as directors of Microbix. Detailed results of the vote are set out below:

In addition, shareholders also approved a resolution appointing the Company''s auditors, Ernst & Young LLP with 99.01% of the votes cast in favour.

About Microbix Biosystems

Microbix Biosystems Inc. specializes in the research, development, marketing and distribution of biological solutions. This includes products for human health applications in the vaccine, therapeutic and diagnostic markets, in addition to a product for the worldwide animal reproduction market. In its revenue generating business, the Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company is also developing a pipeline of innovative technologies and product candidates, including LumiSort semen sexing technology for the livestock industries and Kinlytic, a thrombolytic drug with several approved and potential applications, including the treatment of life-threatening blood clots. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.

Please visit for recent Microbix Biosystems Inc. filings.

For further information, please visit .



Contacts:
Microbix Biosystems Inc.




Vaughn C. Embro-Pantalony
CEO
(905) 361-8910 Ext. 350


Microbix Biosystems Inc.
Jim Currie
CFO
(905) 361-8910 Ext. Ext. 255


Microbix Biosystems Inc.
Stephen Kilmer
Investor Relations
(647) 872-4849

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site
Theratechnologies to Announce Financial Results for the First Quarter of 2017
Bereitgestellt von Benutzer: Marketwired
Datum: 30.03.2017 - 06:51 Uhr
Sprache: Deutsch
News-ID 1495737
Anzahl Zeichen: 2475

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 234 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Microbix Announces Annual Meeting Voting Results
"
steht unter der journalistisch-redaktionellen Verantwortung von

Microbix Biosystems Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Microbix Biosystems Inc.



 

Who is online

All members: 10 563
Register today: 2
Register yesterday: 2
Members online: 0
Guests online: 84


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.